Valneva

Valneva SE is a European specialty vaccine company established in 2013 through the merger of Intercell AG and Vivalis SA. Headquartered in Saint-Herblain, France, it has operational sites in Vienna, Austria, and manufacturing facilities in Scotland, Sweden, and Vienna. The company also has offices in Canada and the United States. Valneva is dedicated to developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs. Its commercial portfolio includes three approved vaccines: IXIARO®/JESPECT® for Japanese encephalitis, IXCHIQ® for Chikungunya, and a cholera vaccine. The company is also advancing several vaccine candidates, including VLA15, the only Lyme disease vaccine in advanced clinical trials. Valneva targets markets with substantial commercial opportunities, particularly in travel vaccines and vector-borne diseases, and aims to contribute to global public health by addressing vaccine-preventable diseases.

Research Saint-Herblain, France ~30 employees NASDAQ: VALN

Work at Valneva in HR or recruiting? Claim this page

Employees
30
-6.2% in the 3 months to Sep 2026
Revenue / employee
$6.1M
Revenue ~$184M
Stock
VALN
NASDAQ
12-month attrition
17.8%
H1B sponsor
NA
Open jobs
10
Last 30 days

Headcount trend

Valneva went from 34 employees in Oct 2024 to 30 in Sep 2026. Apr to Sep 2026: 0 people joined, 4 left.

Org structure

Headcount by department

Other18
Sales4
Operations3
Marketing2
HR2
Finance1

Valneva FAQ

How many employees does Valneva have?

Valneva has about 30 employees, down 6.2% over the 3 months to Sep 2026.

What is Valneva's revenue per employee?

Valneva makes about $6.13M in revenue per employee, based on $183.89M annual revenue and 30 employees.

Is Valneva a public company?

Yes. Valneva is publicly traded under the ticker VALN on NASDAQ.

Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles.